122 related articles for article (PubMed ID: 28739253)
1. Key differences between apoC-III regulation and expression in intestine and liver.
West G; Rodia C; Li D; Johnson Z; Dong H; Kohan AB
Biochem Biophys Res Commun; 2017 Sep; 491(3):747-753. PubMed ID: 28739253
[TBL] [Abstract][Full Text] [Related]
2. Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.
Jattan J; Rodia C; Li D; Diakhate A; Dong H; Bataille A; Shroyer NF; Kohan AB
J Lipid Res; 2017 May; 58(5):853-865. PubMed ID: 28159868
[TBL] [Abstract][Full Text] [Related]
3. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.
Altomonte J; Cong L; Harbaran S; Richter A; Xu J; Meseck M; Dong HH
J Clin Invest; 2004 Nov; 114(10):1493-503. PubMed ID: 15546000
[TBL] [Abstract][Full Text] [Related]
4. Intestinal basolateral lipid substrate transport is linked to chylomicron secretion and is regulated by apoC-III.
Li D; Rodia CN; Johnson ZK; Bae M; Muter A; Heussinger AE; Tambini N; Longo AM; Dong H; Lee JY; Kohan AB
J Lipid Res; 2019 Sep; 60(9):1503-1515. PubMed ID: 31152000
[TBL] [Abstract][Full Text] [Related]
5. Effect of hepatic insulin expression on lipid metabolism in diabetic mice.
Qu S; Zhang T; Dong HH
J Diabetes; 2016 May; 8(3):314-23. PubMed ID: 25851734
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism.
Ramms B; Gordts PLSM
Curr Opin Lipidol; 2018 Jun; 29(3):171-179. PubMed ID: 29547399
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an enhancer element in the human apolipoprotein C-III gene that regulates human apolipoprotein A-I gene expression in the intestinal epithelium.
Bisaha JG; Simon TC; Gordon JI; Breslow JL
J Biol Chem; 1995 Aug; 270(34):19979-88. PubMed ID: 7650015
[TBL] [Abstract][Full Text] [Related]
8. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice.
Tanaka H; Nagashima T; Shimaya A; Urano Y; Shimokawa T; Shibasaki M
Eur J Pharmacol; 2010 Oct; 645(1-3):185-91. PubMed ID: 20655898
[TBL] [Abstract][Full Text] [Related]
9. Sequences and expression of the porcine apolipoprotein A-I and C-III mRNAs.
Trieu VN; Hasler-Rapacz J; Rapacz J; Black DD
Gene; 1993 Jan; 123(2):173-9. PubMed ID: 8428656
[TBL] [Abstract][Full Text] [Related]
10. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.
Chen M; Breslow JL; Li W; Leff T
J Lipid Res; 1994 Nov; 35(11):1918-24. PubMed ID: 7868970
[TBL] [Abstract][Full Text] [Related]
12. PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.
Qu S; Su D; Altomonte J; Kamagate A; He J; Perdomo G; Tse T; Jiang Y; Dong HH
Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E421-34. PubMed ID: 16985262
[TBL] [Abstract][Full Text] [Related]
13. Uncovering the role of apolipoprotein C-III in insulin resistance.
Aguilar-Recarte D; Palomer X; Vázquez-Carrera M
Clin Investig Arterioscler; 2021; 33(2):108-115. PubMed ID: 33303217
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
15. Docosahexaenoic acid suppresses the expression of FoxO and its target genes.
Chen YJ; Chen CC; Li TK; Wang PH; Liu LR; Chang FY; Wang YC; Yu YH; Lin SP; Mersmann HJ; Ding ST
J Nutr Biochem; 2012 Dec; 23(12):1609-16. PubMed ID: 22444500
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph.
Wang F; Kohan AB; Dong HH; Yang Q; Xu M; Huesman S; Lou D; Hui DY; Tso P
Physiol Rep; 2014; 2(3):e00247. PubMed ID: 24760506
[TBL] [Abstract][Full Text] [Related]
18. Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins.
Yao Z
Cardiovasc Hematol Disord Drug Targets; 2012 Dec; 12(2):133-40. PubMed ID: 23030451
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.
Qu S; Altomonte J; Perdomo G; He J; Fan Y; Kamagate A; Meseck M; Dong HH
Endocrinology; 2006 Dec; 147(12):5641-52. PubMed ID: 16997836
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of forkhead box protein O1 (FoxO1) in alcohol-induced intestinal barrier dysfunction.
Wang Y; Tong J; Zou D; Chang B; Wang B; Wang B
Acta Histochem; 2013 Jul; 115(6):557-63. PubMed ID: 23347700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
